Skip to main content
Evidence Snapshot

Replicase polyprotein 1a

CHEMBL3927 SINGLE PROTEIN Severe acute respiratory syndrome-related coronavirus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:57Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3927
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Replicase polyprotein 1a as ChEMBL target CHEMBL3927, mapped to UniProt P0C6U8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Replicase polyprotein 1a
SINGLE PROTEIN · Severe acute respiratory syndrome-related coronavirus
As of 2026-09-13
ChEMBL target ID
CHEMBL3927
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P0C6U8
Replicase polyprotein 1a
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Replicase polyprotein 1a matters

As of 2026-09-13

Replicase polyprotein 1a is reviewed as Replicase polyprotein 1a (UniProt P0C6U8); Replicase polyprotein 1a shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 407 compounds, and 75 assays, with lead potency reaching pChEMBL 8.2.

Disease context
COVID-19

Replicase polyprotein 1a shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include NIRMATRELVIR.

Start review with COVID-19 because it currently carries late clinical support. Linked drugs include NIRMATRELVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 407 compounds, and 75 assays for this target. The dominant activity type is IC50. CHEMBL2435614 is the current potency anchor at pChEMBL 8.2.

Use CHEMBL2435614 as the tractability anchor when discussing potency (pChEMBL 8.2).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 8.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Replicase polyprotein 1a matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P0C6U8, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why COVID-19 is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

407
Total Compounds
75
Total Assays
4
Approved Drugs
IC50: 261.0, KI: 92.0, EC50: 10.0, KD: 3.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2435614
 8.2 Ki —
No preferred name
CHEMBL497141
 8.1 Ki —
No preferred name
CHEMBL5565685
 7.8 IC50 —
No preferred name
CHEMBL5195325
 7.8 IC50 —
No preferred name
CHEMBL2435614
 7.8 Kd —

Approved Drugs

Structure Compound First Approval
NIRMATRELVIR
CHEMBL4802135
 2023
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:57Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3927